Daily Respiratory Research Analysis
Analyzed 195 papers and selected 3 impactful papers.
Summary
Three studies stood out today: a phase 2a randomized trial identified a novel nitroimidazole (JDB0131) with superior early bactericidal activity and good safety versus delamanid for tuberculosis; a Nature Communications study showed IL-17a drives age-related olfactory dysfunction and that IL-17a blockade restores olfactory epithelial regeneration; and a Critical Care Medicine study validated an open-source EHR classifier to identify persistent moderate-to-severe ARDS across health systems.
Research Themes
- Novel anti-infective therapeutics for respiratory diseases
- Immunopathology of aging airway/olfactory epithelium and regenerative reversal
- Data-driven phenotyping and real-time identification of critical respiratory illness
Selected Articles
1. IL-17a induces age-related olfactory dysfunction by impairing regeneration and promoting respiratory metaplasia in mice.
Using aged mice, organoid co-culture, pharmacologic blockade, and T cell–specific IL-17a knockout, the study demonstrates that IL-17a drives inflamm-aging in the olfactory epithelium, impairs neuronal regeneration, and promotes respiratory metaplasia with associated olfactory deficits. Neutralizing IL-17a (Y-320 or antibody) restored neurogenesis and reversed metaplasia, while Th17 co-culture impaired neurogenesis and effects were rescued by IL-17a blockade.
Impact: This mechanistic work identifies IL-17a as a causal driver of presbyosmia and demonstrates reversibility with IL-17a blockade, opening a plausible therapeutic avenue using existing IL-17–targeting agents.
Clinical Implications: Suggests that IL-17 pathway inhibitors could be repurposed to treat age-related olfactory loss and that IL-17a may serve as a biomarker for inflamm-aging of the olfactory epithelium.
Key Findings
- Aging olfactory epithelium exhibits immune cell recruitment and elevated IL-17a, impairing neurogenesis and inducing respiratory metaplasia with olfactory deficits.
- Pharmacologic inhibition or neutralization of IL-17a restored sensory neuronal regeneration and reversed respiratory metaplasia.
- Th17 co-culture impaired neuronal generation in OE organoids; anti–IL-17a antibodies rescued neurogenesis.
- T cell–specific IL-17a knockout facilitated OE regeneration via HBC recruitment and differentiation into GBC.
Methodological Strengths
- Convergent evidence across in vivo aged mouse models, organoid co-culture systems, pharmacologic inhibition, and conditional genetics
- Multi-modal assays (histology, functional olfaction, cellular lineage dynamics) supporting causality
Limitations
- Preclinical mouse and organoid models—human translational efficacy and safety of IL-17 blockade for olfaction remain untested
- Long-term durability of effect and broader sensory/cognitive impacts were not assessed
Future Directions: Prospective human translational studies testing IL-17 pathway inhibitors for presbyosmia; biomarker-driven trials using IL-17a levels; mapping cell-type–specific IL-17 signaling in human OE.
The olfactory epithelium (OE) undergoes life-long renewal and regeneration. This process is supported by the globose basal cells (GBC) during the homeostatic state, as well as horizontal basal cells (HBC) during severe damage. Inflamm-aging refers to the low-grade, chronic and progressive state of heightened pro-inflammation associated with aging. However, the impact of inflamm-aging on OE homeostasis, regeneration, and the inflammatory microenvironment is not fully understood. In this st
2. A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial.
In 52 patients with newly diagnosed TB, JDB0131 (100 mg bid, 200 mg qd, 200 mg bid) demonstrated superior early bactericidal activity versus delamanid over days 0–14, with 200 mg bid showing the clearest advantage. At day 14, all JDB0131 doses achieved superior time-to-positivity. Ninety-one adverse events were attributed to JDB0131 with no serious events, supporting an acceptable safety profile.
Impact: Introduces a third-generation nitroimidazole with superior early bactericidal activity to an approved comparator, providing a promising candidate to strengthen TB regimens.
Clinical Implications: Supports advancing JDB0131 into longer phase 2b/3 trials and evaluation within combination regimens, potentially improving time to culture conversion and shortening therapy.
Key Findings
- JDB0131 200 mg bid showed superior early bactericidal activity versus delamanid over days 0–14.
- At day 14, all JDB0131 dosing cohorts achieved superior time-to-positivity compared with delamanid.
- A total of 91 JDB0131-attributed AEs occurred without serious adverse events, indicating acceptable safety in phase 2a.
Methodological Strengths
- Prospective multicenter randomized controlled design with active comparator
- Multiple efficacy endpoints (log10 CFU decline, time-to-positivity) and dose exploration
Limitations
- Open-label design and small sample size (n=52) limit precision and blinding
- Short 14-day assessment without long-term outcomes or evaluation within full combination regimens
Future Directions: Phase 2b/3 trials to assess culture conversion, relapse-free cure, and optimal combination partners; PK/PD modeling to inform dosing; resistance surveillance.
Tuberculosis (TB) is a contagious disease that threatens human health worldwide. Combination chemotherapy is usually recommended for this disease. Recently, 2 nitroimidazole-based agents, namely, delamanid and pretomanid, have been approved by regulatory agencies. JDB0131 is a novel, structurally optimized third-generation nitroimidazole antituberculosis agent that incorporates the advantages of earlier compounds. This multicenter, prospective, randomized phase 2a trial was conducted to evaluat
3. An Electronic Health Record-Based Classifier for Moderate-to-Severe Acute Respiratory Distress Syndrome With Persistent Hypoxemia.
Across a development cohort (n=924) and an external validation cohort (n=90), an EHR classifier using persistent PaO2/FiO2 ≤150 or use of severe hypoxemia interventions within 24 hours achieved PPV of 71% (95% CI 66–75%) and 66% (95% CI 50–81%), respectively. Using SpO2/FiO2 ≤162 increased case capture but lowered PPV. The open-source tool enables retrospective/prospective identification of persistent moderate-to-severe ARDS.
Impact: Provides a pragmatic, validated, open-source method to identify a high-risk ARDS phenotype from routinely collected data, facilitating quality improvement and trial enrollment.
Clinical Implications: Supports automated screening for persistent severe ARDS for timely escalation (proning, paralysis), resource allocation, and targeted research enrollment using EHR data.
Key Findings
- Primary EHR classifier achieved PPV 71% in development (n=924) and 66% in validation (n=90) cohorts for persistent moderate-to-severe ARDS.
- Classifier leveraging SpO2/FiO2 ≤162 broadened capture but reduced PPV (67% development; 62% validation).
- Operationalized definition includes persistence of hypoxemia or receipt of severe hypoxemia interventions within 24 hours after meeting criteria.
- Tool is open-source for retrospective or prospective use.
Methodological Strengths
- Temporal and geographic external validation across two health systems and six ICUs
- Clinician-adjudicated ARDS reference standard and pragmatic EHR variables
Limitations
- Retrospective design with moderate PPV; validation cohort size was small (n=90) and older (2017)
- Prospective clinical utility and impact on outcomes were not assessed
Future Directions: Prospective implementation studies to assess impact on care processes and outcomes; extension to multi-center real-time screening; refinement with additional physiologic data.
OBJECTIVES: To characterize the performance of an electronic health record (EHR) data-based classifier of persistent moderate-to-severe acute respiratory distress syndrome (ARDS). DESIGN: Retrospective observational study. SETTING: Six ICUs from two health systems. PATIENTS: We included adults receiving greater than or equal to 24 hours of invasive mechanical ventilation (IMV) with a Pao2/Fio2 of less than or equal to 150 mm Hg on Fio2 greater than or equal to 0.6 in the first 72 hours of IMV.